KLDO News and Press, Kaleido Biosciences Inc. From 03/16/22

BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS), today announced appointments to new roles on its executive leadership team, effective immediately. Mark Conley has joined Radius as the Company’s Chief Financial Officer. ...

Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs PR Newswire CAMBRIDGE, Mass. , Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology a...

INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT PR Newswire CAMBRIDGE, Mass. , Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdepende...

LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immu...

The following slide deck was published by Kaleido Biosciences, Inc. in conjunction with this event. For further details see: Kaleido Biosciences (KLDO) Investor Presentation - Slideshow

LEXINGTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immu...

The shares of Seres Therapeutics (MCRB +18.6%) have reached the highest level in more than four months after the company announced the enrollment of the first patient in an early-stage study for microbiome therapy SER-155 in graft-versus-host disease ((GvHD)). Conducted in partnership with Me...

LEXINGTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immu...

Kaleido Biosciences (NASDAQ:KLDO) appointed Alison Long, M.B.B.Ch., Ph.D., to its leadership team as Chief Medical Officer, effective Dec.15. Dr. Long will be responsible for leading the development of Kaleido’s ongoing and future clinical programs, including the development ...

LEXINGTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immu...